Last $4.54 USD
Change Today +0.13 / 2.95%
Volume 235.9K
NEO On Other Exchanges
Symbol
Exchange
Berlin
As of 5:20 PM 02/27/15 All times are local (Market data is delayed by at least 15 minutes).

neogenomics inc (NEO) Snapshot

Open
$4.42
Previous Close
$4.41
Day High
$4.59
Day Low
$4.39
52 Week High
09/10/14 - $6.10
52 Week Low
04/15/14 - $2.95
Market Cap
272.3M
Average Volume 10 Days
232.3K
EPS TTM
$0.03
Shares Outstanding
60.0M
EX-Date
--
P/E TM
145.9x
Dividend
--
Dividend Yield
--
Current Stock Chart for NEOGENOMICS INC (NEO)

Related News

No related news articles were found.

neogenomics inc (NEO) Related Businessweek News

No Related Businessweek News Found

neogenomics inc (NEO) Details

NeoGenomics, Inc., together with its subsidiary, NeoGenomics Laboratories, Inc., operates a network of cancer-focused testing laboratories providing genetic and molecular testing services to hospitals, pathologists, oncologists, urologists, other clinicians and researchers, and other laboratories in the United States. The company performs analyses for hematopoietic cancers, such as leukemia and lymphoma; and solid tumor cancers comprising breast, lung, colon, and bladder cancer. It offers cytogenetics testing services to study normal and abnormal chromosomes and their relationship to diseases; fluorescence in-situ hybridization testing services that focus on detecting and locating the presence or absence of specific DNA sequences and genes on chromosomes; flow cytometry testing services to measure the characteristics of cell populations; immunohistochemistry testing services to identify cell proteins in a tissue section; and molecular testing services that focus on the analysis of DNA and RNA, as well as on the structure and function of genes at the molecular level. The company was founded in 2001 and is headquartered in Fort Myers, Florida.

neogenomics inc (NEO) Top Compensated Officers

Executive Chairman and Chief Executive Office...
Total Annual Compensation: $557.0K
Chief Financial Officer
Total Annual Compensation: $305.5K
Chief Medical Officer and Director of Researc...
Total Annual Compensation: $92.5K
Chief Compliance Officer, Executive Vice Pres...
Total Annual Compensation: $72.5K
Compensation as of Fiscal Year 2013.

neogenomics inc (NEO) Key Developments

Neogenomics Inc. Reports Consolidated Unaudited Earnings Results for the Fourth Quarter and Year Ended December 31, 2014; Provides Revenue Guidance for 2015

Neogenomics Inc. reported consolidated unaudited earnings results for the fourth quarter and year ended December 31, 2014. For the quarter, the company reported net revenue was $25,000,000 against $18,323,000 a year ago. Income from operations was $1,319,000 against $1,204,000 a year ago. Income before taxes was $1,126,000 against $963,000 a year ago. Net income was $1,047,000 against $857,000 a year ago. Diluted per share was $0.02 against $0.02 a year ago. EBITDA was $2,820,000 against $2,334,000 a year ago.  Adjusted EBITDA (non-GAAP) was $2,773,000 against $2,733,000 a year ago. For the year, the company reported net revenue was $87,069,000 against $66,467,000 a year ago. Income from operations was $2,218,000 against $3,174,000 a year ago. Income before taxes was $1,289,000 against $2,185,000 a year ago. Net income was $1,132,000 against $2,033,000 a year ago. Diluted per share was $0.02 against $0.04 a year ago. Net cash provided from operating activities was $9,450,000 against $2,227,000 a year ago. EBITDA was $7,914,000 against $7,586,000 a year ago. Adjusted EBITDA (non-GAAP) was $9,176,000 against $8,515,000 a year ago. The company expects 2015 revenue of $103 - $108 million. This guidance includes an estimated $6 - $8 million reduction in revenue from all payers as a result of billing the new AMA FISH CPT codes that were effective as of January 1, 2015.

Neogenomics Mulls Acquisitions

Neogenomics Inc. (NasdaqCM:NEO) is looking for acquisitions. Chairman and Chief Executive Officer, Douglas M. VanOort said, “In addition, we are increasingly focused on exploring mergers and acquisitions as a means to increase our scale and diversify our business. We continue to be enthusiastic about the prospects for our business.”

NeoGenomics, Inc. Revises Consolidated Earnings Guidance for the Fourth Quarter of Fiscal 2014

NeoGenomics Inc. revised consolidated earnings guidance for the fourth quarter of fiscal 2014. The company announced that it was raising its previously issued revenue and earnings per share guidance for the fourth quarter of 2014. The company now expects revenue of approximately $25 million and earnings per share of approximately $0.01 - $0.02 for the fourth quarter. Previously, the company had issued revenue guidance of $23.0 million to $24.5 million and earnings per share guidance of $0.00 to $0.01 per share. On a consolidated basis, including the results of the company’s newly acquired PathLogic business, it is expecting approximately 36% year over year revenue growth in the fourth quarter. Approximately 23% of this growth is coming from the company’s core NeoGenomics business and the remainder from PathLogic.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
NEO:US $4.54 USD +0.13

NEO Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Enzo Biochem Inc $3.06 USD +0.01
Psychemedics Corp $16.41 USD +0.58
Response Genetics Inc $0.62 USD -0.0436
Rosetta Genomics Ltd $3.41 USD -0.10
Signal Genetics Inc $2.70 USD -0.21
View Industry Companies
 

Industry Analysis

NEO

Industry Average

Valuation NEO Industry Range
Price/Earnings 100.0x
Price/Sales 3.0x
Price/Book 4.4x
Price/Cash Flow 233.1x
TEV/Sales 2.6x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact NEOGENOMICS INC, please visit www.neogenomics.org. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.